Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|April 27, 2017
ACO Growth and Specialty Pharmacies
Author(s)Lauren Santye, Assistant Editor
Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses how specialty pharmacies will be impacted by the growth of accountable care organizations.
Advertisement
Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses how specialty pharmacies will be impacted by the growth of accountable care organizations.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
2
New Data Reshape Nonstatin Lipid Therapy Choices
3
After 180 Years, Multiple Myeloma Gets a Definition of Cure
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5